Parkinson’s Disease: A Review on Ongentys®

Abstract

Aim: Parkinson’s disease (PD) is an auto neuro-degenerative disease/disorder, mainly affects voluntary movements and behavioral functions in the elderliness. Previous studies narrated various aspects of Parkinson’s disease but they could not explain the Parkinson’s disease along with the Off-episode state and its management by using ongentys. In this review paper authors elaborately and comprehensively explained about Off-episode condition and its management by using Ongentys medicine. Main body: In 25-50% population of Patient with PD it is found that they have developed OFF-Episode (Wearing-OFF) phenomenon in the first two years of treatment and after 10 years most of the patients were with off-episode condition. In this condition due to various known and unknown reasons medications used for PD are become ineffective between dose regimens that enable the symptoms of PD before next dose of Levodopa. To overcome this condition various medications are available in the market like- Entacapone, Tolcapone etc. A new approach has been developed for managing Off-episode problem in the PD patients i.e. Opicapone (Ongentys®). Opicapone is COMT [Catechol-O-methyltransferase]: enzyme inhibitor, which prevents the degradation of Levodopa peripherally. COMT enzyme metabolizes Levodopa into 3-O-methyldopa by methylation reaction peripherally as well as in the CNS region. Ongentys is used as a adjunctive with levodopa/carbidopa formulations and administered at bedtime only. Conclusion: In this review authors mainly focus on the Ongentys® and its utilization in the management of off-episode state in PD patients. Authors also cover little bit about sign and symptoms, diagnostic tools, epidemiology of Parkinson’s disease and drugs which may be used for the treatment of PD.